Original Article

Mendelian Randomization Analysis Reveals the Causal Relationships Between Autoimmune Diseases and Idiopathic Thrombocytopenic Purpura and the Mediating Role of Immune Cells

Kaiqing Yan[1], Lin Sun[1], Wenyu Gao[2], Qianqian Cui[2], Hongxiu Liu[2], Yun Tian[1], Siyu Gao[1], Yanping Ma[2]

Abstract

Background: Idiopathic thrombocytopenic purpura (ITP) is related to multiple autoimmune diseases clinically, yet the causal relationship remains unclear. This study employed Mendelian randomization (MR) to explore the genetic causal relationship between autoimmune diseases and ITP and potential mediators in the European population.

Methods: Summary statistics of 10 common autoimmune diseases and ITP were extracted for analysis. Bidirectional two-sample MR and two-step MR were conducted.

Results: Multiple sclerosis (MS, inverse variance weighted [IVW]: odds ratio (OR)=5.840E+16, false discovery rate (FDR)=0.049), celiac disease (CeD, IVW: OR=1.173, FDR=0.023), systemic lupus erythematosus (SLE, IVW: OR=1.068, FDR=0.049), and autoimmune hyperthyroidism (AIH, IVW: OR=1.265, FDR=0.037) are risk factors for ITP. Rheumatoid arthritis (RA, IVW: OR=1.112, FDR=0.055) may be a potential risk factor. Crohn's disease (CD, IVW: OR=0.816, FDR=0.049), ulcerative colitis (UC, IVW: OR=0.709, FDR=0.042), and psoriasis (PsO, IVW: OR=1.690E−04, FDR=0.042) are protective factors. No clear causal relationship between ankylosing spondylitis (AS, IVW: OR=1.016, FDR=0.553) and type 1 diabetes mellitus (T1DM, IVW: OR=1.035, FDR=0.577) and ITP. Immune cells act as mediators between CeD and ITP and CD and ITP.

Conclusion: This study clarified the relationship between some autoimmune diseases and ITP and the mediating role of immune cells.

Keywords: Celiac disease, Crohn's disease, idiopathic thrombocytopenic purpura, immune cell mediation, Mendelian randomization analysis, psoriasis

ORCID iDs of the authors:
K.Y. 0009-0005-8921-7699;
L.S. 0009-0005-7852-3674;
W.G. 0009-0000-2780-4832;
Q.C. 0009-0005-5260-2198;
H.L. 0009-0005-9502-1764;
Y.T. 0009-0006-3934-8671;
S.G. 0009-0007-7032-8350;
Y.M. 0000-0003-3174-3109.

[1] Second School of Clinical Medicine, Shanxi Medical University, Shanxi, China
[2] Fifth School of Clinical Medicine, Shanxi Medical University, Shanxi, China

Corresponding author:
Yanping Ma
E-mail: myanp18@163.com

Introduction

Idiopathic thrombocytopenic purpura is an acquired autoimmune hemorrhagic disorder characterized by a reduction in platelet counts and an increased risk of bleeding.[1] The incidence of bleeding-induced hospitalization within 5 years after diagnosis is approximately 15%.[2] Traditional treatment relies on immunosuppression. Older immunosuppressants cannot change the natural course of the disease and affect the quality of life of patients. New therapies such as thrombopoietin receptor agonists can improve the quality of life of patients, but they are costly and there are issues of drug resistance.[3] Therefore, early prevention of ITP and exploration of new treatment regimens are needed.

To prevent the occurrence and progression of ITP, scholars have explored its risk factors. Previous studies have indicated that ITP is associated with a series of autoimmune diseases.[4-10] In observational studies, there are multiple confounding factors between autoimmune diseases and ITP, such as age, sex, viral infection, drugs, and the environment.[11] These factors may affect the correct judgment of the relationship between the two. Reverse causal bias may also mislead the understanding of the relationship between autoimmune diseases and ITP. More scientific research methods are needed to reduce its impact. To analyze the causal relationship between ITP and autoimmune diseases more effectively for prevention and management, we used MR to clarify this issue.

Idiopathic thrombocytopenic purpura is closely related to the occurrence and progression of multiple immune cells. In ITP, abnormal activation of B cells leads to the production of a large number of anti-platelet

Yan et al. MR on AD, ITP and Immune Cells

Eur J Rheumatol 2025;12:1-7

antibodies, causing platelet destruction. The imbalance of T cell subsets results in the inability to effectively regulate the autoimmune response. In addition, macrophages mediate platelet destruction.[1] Therefore, this study also deeply explores the intermediary role of 731 immune cells in autoimmune diseases that mediate ITP, which is of great significance for formulating more effective treatment strategies and accurately assessing the disease condition.

Mendelian randomization employs genetic variations as instrumental variables (IVs) for the purpose of assessing the causal relationship between risk factors (exposures) and outcomes. Given that single nucleotide polymorphisms (SNPs) are randomly assigned at conception, MR is less prone to confounding, measurement error, and reverse causality than many other observational methods are.[12] Given that immune cells play an important role in autoimmune diseases, we also performed two-step MR to estimate the proportion of immune cells contributing to autoimmune disease-mediated ITP. The complexity of the MR framework can be understood from Figures 1 and 2.

Material and Methods

Source of Data
The datasets of ITP (ebi-a-GCST90018865), PsO (ukb-a-100), CD (finn-b-K11_KELACROHN), UC (finn-b-ULCERNAS), MS

Figure 1. Overview of the research design of two-way two-sample MR. The MR framework is based on three fundamental MR assumptions. MR, Mendelian randomization; SNP, single nucleotide polymorphism.

(ukb-17670), CeD (ebi-a-1058), RA (bbj-a-73), SLE (ebi-a-GCST003156), AIH (finn-b-AUTO-IMMUNE_HYPERTHYROIDISM), AS (finn-b-M13_ANKYLOSPON_STRICT), and T1D (finn-b-E4_DM1) originate from the Open Genome-Wide Association Study (GWAS) database of the Integrative Epidemiology Unit (IEU) (https://gwas.mrcieu.ac.uk/). The ebi-a-GCST90018865 dataset encompasses 24 199 770 SNPs derived from 489 424 samples. The ukb-a-100 dataset comprises 10 894

596 SNPs from 337 159 samples. The finn-b-K11_KELACROHN dataset contains 16 380 466 SNPs from 218 792 samples. The finn-b-ULCERNAS dataset consists of 16 380 457 SNPs from 212 507 samples. The ukb-b-17670 dataset includes 9 851 867 SNPs from 462 933 samples. The ieu-a-1058 dataset consists of 38 037 SNPs from 24 269 samples. The bbj-a-73 dataset comprises 8 747 962 SNPs from 8383 samples. The ebi-a-GCST003156 dataset contains 7 071 163 SNPs from 14 267 samples. The

Main Points

- Bidirectional two-sample MR analysis revealed the causal associations between 10 autoimmune diseases and ITP.
- The causal effects of MS, CeD, SLE, and AIH on the risk of ITP have been substantiated.
- Rheumatoid arthritis may potentially be a risk factor for ITP.
- PsO, CD, and UC are protective factors for ITP.
- All results meet the requirements for heterogeneity and horizontal pleiotropy.
- There is insufficient evidence to establish a causal relationship between AS and T1DM and ITP. No significant reverse causal relationships were detected.
- The two-step MR approach revealed that immune cells act as mediators between CeD and ITP as well as between CD and ITP.

Figure 2. Overview of the two-step MR study design. Intermediate effect = $\beta2 \times \beta3$. Intermediate ratio = $\beta2 \times \beta3/\beta1$. Legend of scatter plot: Inverse variance weighted; MR Egger; Simple mode; Weighted median; Weighted mode. Legend of funnel plot: Inverse variance weighted; MR Egger.

fin-b-autoimmune_hyperthyroidism dataset includes 16 380 189 SNPs from 173 938 samples. The fin-b-m13_ankylospon_strict dataset contains 16 380 466 SNPs from 218 030 samples. The fin-b-e4_dm1 dataset comprises 16 380 008 SNPs from 189 113 samples. Details of the above datasets are given in Table 1. The data for MR analysis originated from the public genome-wide association studies (GWAS) database (https://gwas.mrcieu.ac.uk). In the original studies, relevant ethical approvals and informed consent of patients were obtained.

Genetic Instrument Selection

For forward two-sample MR analysis, the extract_instruments function of the TwoSampleMR software package was employed for the reading and filtering of exposure factors ($P < 5 \times 10^{-8}$).[13] In the reverse two-sample MR analysis, as an insufficient number of summary statistics for ITP could not be extracted, the threshold was adjusted to $P < 1 \times 10^{-5}$.[14] Linkage disequilibrium analysis (LDA) was used to eliminate single nucleotide polymorphisms (SNPs) ($r^2 = 0.001$, kb = 10 000), and all the F statistics were greater than 10 (Supplementary Table 1). When selecting exposed SNPs, we adopted three core assumptions: (1) genetic variations are closely associated with the exposure of interest; (2) they have no association with any known or potential confounding factors; and (3) except for the exposure, genetic variations have no relation to other pathways that affect the outcome and cannot be directly correlated with the outcome. Detailed SNP data can be found in Supplementary Table 1.

Bidirectional Two-Sample MR Analysis, Sensitivity Analysis and Visualization of Results

First, five distinct MR approaches, namely, MR–Egger,[15] weighted median,[16] inverse variance weighted (IVW),[17] simple mode, and weighted mode,[18] were utilized to investigate the causal associations between 10 autoimmune disorders and ITP, with IVW being of the utmost significance. In MR studies, OR is an important statistical measure used to quantify the strength of the association between exposure factors and outcomes, and it helps researchers infer causal relationships. An OR > 1 indicates that the exposure factor constitutes a risk factor, whereas an OR < 1 indicates that the exposure factor serves as a protective factor. The results are presented via scatter plots and forest plots in supplementary materials.

Furthermore, a sensitivity analysis was performed to evaluate the reliability of the MR findings. First, the horizontal pleiotropy test was executed in R via the TwoSampleMR function mr_pleiotropy_test. If $P > .05$, it implies the absence of horizontal pleiotropy, indicating that there are no confounding factors in this research.[17] Additionally, the Cochran's Q test was utilized for heterogeneity assessment. Specifically, in the Cochran's Q test, when the p value is greater than 0.05, heterogeneity is nonexistent. If heterogeneity existed ($P < .05$), the IVW test was adopted to test the random effects. In addition, a "Leave-one-out" analysis was conducted by progressively eliminating each SNP. If the impact of the remaining SNPs on the outcome variable does not undergo significant changes, this suggests that the MR analysis results are dependable. Next, we also conducted funnel plot analysis to detect potential publication bias. Finally, FDR is an important measure in Mendelian randomization studies as it helps control for the risk of false positives and provides a more accurate interpretation of the results. The p value of the univariate analysis results was corrected via the FDR method (a p value of FDR < 0.05 indicates statistical significance), which improved the reliability of the positive results. When P < FDR < 0.05, there is a significant association between exposure and outcome, which provides strong evidence for a possible causal relationship between exposure factors and outcomes. When P < 0.05 < FDR, there is a suggestive association between exposure and outcome. Although it does not reach the traditional statistical significance level, the result still has a certain suggestive effect, indicating a possible association.[19]

Mediation Analysis

Additionally, we employed a two-step MR study to explore whether the 731 kinds of immune cells mediate the causal routes of these eight diseases (PsO, CD, UC, MS, CeD, RA, SLE, and AIH) as exposures to ITP. The total effect was decomposed into the mediating effect and the direct effect. The formula for computing the direct effect is as follows: Direct effect = Total effect − Mediating effect.[20] The mediating roles of the exposure on ITP were subsequently disaggregated into (i) the causal effect of exposure to the mediator (β2) and (ii) the causal effect of the mediator on the outcome (β3). Mediation effect = β2 × β3, Intermediate ratio = β2 × β3/β1.[20]

Results

Bidirectional Two-Sample MR Analysis

The IVW method shows significant associations between PsO and ITP (β = −8.686, se = 3.639, odds ratio (OR): 1.690E−04, 95% confidence interval (CI): 1.350E −07 to 0.211, $P = .017$, FDR = 0.42), between UC and ITP (β = −0.344, se = 0.149, OR: 0.709, 95% CI: 0.530 to 0.949, $P = .021$, FDR = 0.042), between CD and ITP

Table 1. Detailed Information About the Datasets

Trait	Year	Population	Author	GWAS ID	Sample Size	SNP
ITP	2021	European	Sakaue S	ebi-a-GCST90018865	489 424	24199770
PSO	2017	European	Neale	ukb-a-100	337 159	10894596
CD	2021	European	NA	finn-b-K11_KELACROHN	218 792	16380466
UC	2021	European	NA	finn-b-ULCERNAS	212 507	16380457
MS	2018	European	Ben Elsworth	ukb-b-17670	462 933	9851867
CeD	2011	European	Trynka	ieu-a-1058	24 269	38037
RA	2019	European	Ishigaki K	bbj-a-73	8383	8747962
SLE	2015	European	Bentham J	ebi-a-GCST003156	14 267	7071163
AIH	2021	European	NA	finn-b-AUTOIMMUNE_HYPERTHYROIDISM	173 938	16380189
AS	2021	European	NA	finn-b-M13 ANKYLOSPON_STRICT	218 030	16380466
T1DM	2021	European	NA	finn-b-E4_DM1	189 113	16380008

Yan et al. MR on AD, ITP and Immune Cells

Eur J Rheumatol 2025;12:1-7

Table 2. Summary of inverse variance weighted results in forward two-sample MR analysis

outcome	exposure	β	se	or	or_lci95	or_uci95	pval	FDR
ITP	PSO	- 8.686	3.639	1.690E - 04	1.350E - 07	0.211	0.017	0.042
ITP	UC	- 0.344	0.149	0.709	0.530	0.949	0.021	0.042
ITP	CD	- 0.203	0.099	0.816	0.673	0.990	0.039	0.049
ITP	CeD	0.159	0.056	1.173	1.050	1.310	0.005	0.023
ITP	SLE	0.066	0.031	1.068	1.005	1.136	0.034	0.049
ITP	MS	38.606	17.706	5.840E+16	49.513	6.890E+31	0.029	0.049
ITP	AIH	0.235	0.081	1.265	1.080	1.483	0.004	0.037
ITP	RA	0.106	0.044	1.112	1.020	1.214	0.017	0.055
ITP	AS	0.106	0.027	1.016	0.963	1.072	0.553	0.553
ITP	T1DM	0.035	0.054	1.035	0.931	1.151	0.519	0.577

(β=−0.203, se=0.099, OR: 0.816, 95% CI: 0.673 to 0.990, P=0.039, FDR=0.049), between CeD and ITP (β=0.159, se=0.056, OR: 1.173, 95% CI: 1.050 to 1.310, P=.005, FDR=0.023), between SLE and ITP (β=0.066, se=0.031, OR: 1.068, 95% CI: 1.005 to 1.136, P=.034, FDR=0.049), between MS and ITP (β=38.606, se=17.706, OR: 5.840E+16, 95% CI: 49.513 to 6.890E+31, P=.029, FDR=0.049), and between AIH and ITP respectively (β=0.235, se=0.081, OR: 1.265, 95% CI: 1.080 to 1.483, p=0.004, FDR=0.037). The IVW method shows a suggestive association between RA and ITP (β=0.106, se=0.044, OR: 1.112, CI: 1.020 to 1.214, P=.017, FDR=0.055). The IVW method shows that there is currently insufficient evidence to prove a causal relationship between AS (β=0.016, se=0.027, OR: 1.016, 95% CI: 0.963 to 1.072, P=.553, FDR=0.553) and T1DM (β=0.035, se=0.054, OR: 1.035, 95% CI: 0.931 to 1.151, P=.519, FDR=0.577) and ITP. Refer to Supplementary Figures 1-16 for visualization of the results (forest plots, scatter plots). For forward MR analysis, the results of methods such as MR–Egger, weighted median, simple mode, and weighted mode are presented in detail in Table 2 Supplementary Table 2. In reverse MR analysis, there is insufficient evidence to prove a reverse causal relationship between

these ten autoimmune diseases and ITP. See Supplementary Table 3. (Insufficient summary statistics of CeD could not be extracted for MR analysis.)

Sensitivity Analyses
A comprehensive sensitivity analysis is performed to assess the reliability of the causal relationship obtained due to violation of the IV hypothesis. First, via MR–Egger regression intercept analysis, there was no evidence of horizontal pleiotropy among IVs. The P value of all associated MR–Egger intercepts was >.05 (Supplementary Table 4). Second, the P value (>.05) of Cochran's Q test basically excludes heterogeneity (Supplementary Table 5). Next, the results of the leave-one-out method further verify the persistence of the results (leave-one-out analysis plots in Supplementary Figures 17-24). Finally, The funnel plot shows good symmetry (funnel plots in Supplementary Figures 25-32). In conclusion, the stability of the results is supported by strict sensitivity analysis.

A Two-Step MR
The Immune Effector Mechanism in ITP
All the diseases were subjected to reverse MR studies, and no significant causal relationships were found. This ensures that the

mediation pathway can proceed only in the direction of exposure → mediator → outcome. It is known that immune cells play important roles in the pathogenesis of autoimmune diseases. Therefore,we explored the relationship between 731 types of immune cells and ITP to identify potential mediators in the pathway linking exposure and outcome. The data of 731 types of immune cells can be openly obtained from the GWAS Catalogue (https://www.ebi.ac.uk/gwas/, accession numbers from GCST90001391 to GCST90002121). The reading and filtering of the exposure factors are performed via the extract_instruments function of the TwoSampleMR software package ($P < 5 \times 10^{-8}$). Instrumental variables are removed via LDA (r^2=0.001, kb=10 000) and comply with three core assumptions. IVW MR analysis revealed significant correlations: (1) Switched memory B cell %lymphocyte is associated with ITP (β=0.503, se=0.242, OR=1.653, 95% CI 1.029 to 2.656, P=.038, FDR=0.044); (2) B cell %CD3− lymphocyte is associated with ITP (β=−0.170, se=0.073, OR= 0.843, 95% CI 0.730 to 0.974, P=.020, FDR=0.029); (3) CD20 on IgD+ CD38+ B cell is associated with ITP (β=−0.420, se=0.123, OR=0.657, 95% CI 0.516-0.837, P=.001, FDR=0.002); (4) CD20 on IgD+ CD24− B cell is associated with ITP (β=−0.559,

Table 3. Summary of Inverse Variance Weighted Results from the MR Analysis of Immune Cells and ITP

outcome	exposure	β	se	or	or_lci95	or_uci95	pval	FDR
ITP	Switched memory B cell %lymphocyte	0.503	0.242	1.653	1.029	2.656	0.038	0.044
ITP	B cell %CD3-lymphocyte	- 0.170	0.073	0.843	0.730	0.974	0.020	0.029
ITP	CD20 on IgD+CD38+B cell	- 0.420	0.123	0.657	0.516	0.837	0.001	0.002
ITP	CD20 on IgD+CD24-B cell	- 0.559	0.119	0.572	0.452	0.723	2.880E - 06	2.016E - 05
ITP	CD20 on naive-mature B cell	- 0.427	0.136	0.653	0.500	0.851	0.002	0.004
ITP	CD20 on IgD+B cell	- 0.404	0.129	0.667	0.518	0.860	0.002	0.003
ITP	CD25 on IgD+CD38+B cell	0.572	0.288	1.771	1.008	3.113	0.047	0.047

Eur J Rheumatol 2025;12:1-7

Yan et al. MR on AD, ITP and Immune Cells

Table 4. Summary of Inverse Variance Weighted Results in MR Analysis of Exposures and Mediators

outcome	exposure	β	se	or	or_lci95	or_uci95	pval	FDR
CD20 on IgD+CD24-B cell	CD	0.106	0.041	1.112	1.027	1.205	0.009	0.018
CD20 on IgD+B cell	CD	0.101	0.040	1.106	1.022	1.198	0.012	0.012
CD20 on IgD+CD24-B cell	CeD	- 0.121	0.031	0.886	0.833	0.942	1.018E - 04	1.357E - 04
CD20 on IgD+CD38+B cell	CeD	- 0.131	0.031	0.877	0.825	0.932	2.459E - 05	9.835E - 05
CD20 on naive-mature B cell	CeD	- 0.128	0.031	0.880	0.828	0.935	4.106E - 05	8.212E - 05
CD20 on IgD+B cell	CeD	- 0.121	0.031	0.886	0.834	0.942	1.152E-04	1.152E-04

se = 0.119, OR = 0.572, 95% CI 0.452 to 0.723, P = 2.880E−06, FDR = 2.016E−05); (5) CD20 on naive-mature B cell is associated with ITP (β = −0.427, se = 0.136, OR = 0.653, 95% CI 0.500 to 0.851, P = 0.002, FDR = 0.004); (6) CD20 on IgD+ B cell is associated with ITP (β = −0.404, se = 0.129, OR = 0.667, 95% CI 0.518 to 0.860, P = .002, FDR = 0.003); (7) CD25 on IgD+ CD38+ B cell is associated with ITP (β = 0.572, se = 0.288, OR = 1.771, 95% CI 1.008 to 3.113, P = .047, FDR = 0.047). The results mainly refer to the IVW method. The results refer mainly to the IVW method. For the results of the other methods, Table 3 see Supplementary Table 6 for details. No significant causal relationships were found between other immune cells and ITP. No evidence of horizontal pleiotropy and heterogeneity was found (Supplementary Tables 7 and 8). See Supplementary Table 9 for the F statistics and detailed SNPs.

Subsequently, the relationship between Switched memory B cell %lymphocyte, B cell %CD3 - lymphocyte, CD20 on IgD+ CD38+ B cell, CD20 on IgD+ CD24− B cell, CD20 on naive - mature B cell, CD20 on IgD+ B cell, CD25 on IgD+ CD38+ B cell and PsO, CD, UC, CeD, RA, MS, SLE, and AIH was studied. Among the studied components, the IVW method revealed that CeD was associated with CD20 on IgD+ CD38+ B cell (β = −0.131, se = 0.031, OR = 0.877, 95% CI 0.825 to 0.932, p = 2.459E05, FDR = 9.835E−05); CeD was associated with CD20 on IgD+ CD24− B cell (β = −0.121, se = 0.031, OR = 0.886, 95% CI 0.833 to 0.942, P = 1.018E−04, FDR = 1.357E−04); CeD was associated with CD20 on IgD+ B cell (β = −0.121, se = 0.031, OR = 0.886, 95% CI 0.834 to 0.942, p = 1.152E−04, FDR = 1.152E−04); and CeD was associated with CD20 on naive-mature B cell (β = −0.128, se = 0.031, OR = 0.880, 95% CI 0.828 to 0.935, P = 4.106E−05, FDR = 8.212E05). CD was associated with CD20 on IgD+ B cell (β = 0.101, se = 0.040, OR = 1.106, 95% CI 1.022 to 1.198, P = .012, FDR = 0.012), CD was associated with CD20 on IgD+ CD24- B cell (β = 0.106, se = 0.041, OR = 1.112, 95% CI 1.027-1.205, P = 0.009, FDR = 0.018). See Supplementary

Table 10 for the F statistics and detailed SNPs. (The results of MR–Egger, weighted median, simple model and weighted model are shown in Table 4 Supplementary Table 11).

Mediator analysis revealed that CD20 on IgD+ CD38+ B cell played a partial mediating role in the causal pathway from CeD to ITP. The mediating effect of the delta method was 0.055 (se: 0.021, 95% CI 0.019-0.102, or: 1.057, or_lci95: 1.019, or_uci95: 1.107), and the proportion of the mediating effect was 34.50%. CD20 on IgD+ CD24- B cell plays a partial mediating role in the causal pathway from CeD to ITP. The mediating effect of the delta method was 0.056 (se: 0.022, 95% CI 0.019-0.105, or: 1.058, or_lci95: 1.019, or_uci95: 1.111), and the proportion of the mediating effect was 35.13%. CD20 on IgD+ B cell plays a partial mediating role in the causal pathway from CeD to ITP. The mediating effect of the delta method was 0.035 (se: 0.02, 95% CI 0.001 to 0.079, or: 1.036, or_lci95: 1.001, or_uci95: 1.082), and the proportion of the mediating effect was 21.96%. CD20 on naive-mature B cell partially mediated the causal pathway from CeD to ITP. The mediating effect of the delta method was 0.039 (se: 0.022, 95% CI 0.001-0.087, or: 1.039, or_lci95: 1.001, or_uci95: 1.091), and the percentage of the mediating effect was 24.46%. CD20 on IgD+ B cell plays a partial mediating role in the causal pathway from CD to ITP. The mediating effect of the delta method was −0.041 (se: 0.022, 95% CI 0.09-0.006, or: 0.96, or_lci95: 0.914, or_uci95: 0.994), and the proportion of the mediating effect was 20.19%. CD20 on IgD+ CD24- B cell plays a partial mediating role in the causal pathway from CD to ITP. The mediating effect of the delta method was −0.059 (se: 0.027, 95% CI 0.117-0.013, or: 0.942, or_lci95: 0.89, or_uci95: 0.987), and the percentage of the mediating effect was 29.05%.

Discussion

Exploring risk factors for ITP is crucial. This study establishes causal links between certain autoimmune diseases and ITP. Rheumatoid arthritis shows no correlation. MS, CeD, SLE, and AIH affect ITP risk. PsO, CD, and UC are protective.

CD20 on specific B cells mediates associations between CeD and ITP and between CD and ITP.

Studies show an increased platelet count in psoriasis patients. IL-23 binds to receptors, activating JAK2 and leading to psoriasis.[21] JAK2 is activated with the thrombopoietin receptor, promoting platelet production.[22] In this context, a scientific hypothesis was put forward: The JAK-STAT signaling pathway plays a crucial role in regulating the physiological state of platelets in patients with PSO, and this regulation may be one of the reasons why PSO patients are less likely to suffer from ITP. It should be emphasized, however, that at present this is merely a speculation based on the existing research data. Although these findings provide a new potential direction for the research on the treatment of ITP, it must recognize that the mechanisms of reactive thrombocytosis caused by inflammation may be complex and diverse in different diseases. Therefore, more in-depth studies are needed to comprehensively analyze the differences of this potential mechanism in different diseases. Studies have shown that the platelet counts in patients with UC and CD are increased, and the levels of thrombopoietin in patients with inflammatory bowel disease (IBD) are higher than those in the general population, which may be the reason why patients with UC and CD are less likely to suffer from ITP.[5,23] Remarkably, an MR study conducted by Li H et al[24] demonstrated that genetically predicted UC and CD are both positively correlated with ITP. The likely reason for this disparity may be that geography and ethnicity can modify causal relationships. In recent years, the relationship between ITP and CeD has attracted increasing attention.[25] Combined with the results of MR, it is reasonable to believe that patients with CeD may develop ITP. Therefore, patients with CeD should be vigilant about the occurrence and progression of ITP. For celiac patients with ITP, a gluten-free diet can be used to treat the symptom of decreased platelet count. This can not only ensure the life safety of patients and improve their quality of

Yan et al. MR on AD, ITP and Immune Cells

Eur J Rheumatol 2025;12:1-7

life, but also reduce family economic burdens and social fiscal expenditures. This will be of great significance for clinicians. Several studies from different countries have evaluated the causal relationship between ITP and SLE, but no consensus has been reached yet.[6,7] From the perspective of MR studies, it has been confirmed that SLE is a risk factor for ITP and there is no reverse causal relationship. Studies have shown that the prevalence of MS in patients with ITP is 25 times higher than that expected in the general population.[9] However, the exact connection between the coexistence of the two has not been fully explained. MS has been identified as a potential cause of ITP in our study. Nevertheless, reports on MS combined with ITP in the literature are limited. Future clinical studies with larger sample sizes are still needed to confirm these findings and explore the underlying mechanisms. Study have found that ITP can coexist with AIH, and platelet-associated IgG and/or specific circulating platelet autoantibodies can be detected in patients with AIH. Treating underlying thyroid diseases may improve thrombocytopenia.[10] The authors have confirmed the unidirectional causal relationship between AIH and ITP. It is recommended to perform routine assessment of thyroid function and actively treat thyroid diseases in patients with ITP.[10] MR analysis results suggest that RA may be a risk factor for ITP. In clinical settings, thrombocytopenia in patients with RA is a rare complication. It may be that the frequent use of corticosteroid treatment in these patients masks the association with thrombocytopenia. The relationship between RA and ITP is uncertain and requires further exploration.

In ITP, the autoantibodies against self-antigens produced by autoreactive B cells, especially the autoantibodies against glycoprotein IIb (GPIIb)/IIIa and/or GPIb/IX, that is, the loss of immune tolerance to platelet self-antigens, constitute a key upstream step in the pathophysiology of ITP. In addition, abnormalities in B-cell subsets, such as defective regulatory B cells (Bregs), the expansion of memory B cells, and long-lived plasma cells, play a crucial role in the production of autoantibodies in ITP.[1] Studies have found that B cells play a role in the pathogenesis of celiac disease by promoting the cytotoxic potential of intraepithelial lymphocytes (IELs) and the development of villous atrophy (VA).[26]

Although these studies highlight the important role of immune cells and their complex phenotypes in disease development, the results may be influenced by potential confounding factors and limited sample sizes. Therefore, we designed a two-step MR study to investigate the mediating role of 731 immune cell phenotypes, aiming to provide new insights into the pathogenesis and treatment methods of ITP. The results of the two-step MR study revealed that the association between CD and ITP is mediated by disorders of CD20 on IgD+ CD24- B cell and CD20 on IgD+ B cell; the association between CeD and ITP is mediated by disorders of CD20 on IgD+ CD38+ B cell, CD20 on IgD+ CD24- B cell, CD20 on IgD+ B cell, and CD20 on naive-mature B cell.

CD20 plays a crucial role in the activation, proliferation and differentiation processes of B cells.[27] B lymphocytes can destroy platelets by generating autoantibodies against platelets.[1] Clinically, anti-CD20 monoclonal antibodies can bind to CD20 on the surface of B cells, inducing apoptosis of B cells, thereby alleviating the destruction of platelets.[28] In healthy people, B cells switching to the IgD isotype are mainly autoreactive. A small portion of B cells form Cδ-cs cells through conversion in a specific switch region.[29] Human Cδ-CS B lymphocytes are autoreactive, and their generation may be related to immune tolerance mechanisms.[30] CD38 participates in the regulation of autoimmunity. Current studies have confirmed that the elimination of CD38 by anti-CD38 monoclonal antibodies can downregulate the production of autoantibodies and restore immune balance by reducing platelet destruction and increasing platelet count.[31]

Although this study has alleviated some of the limitations of traditional observational studies, there are still some deficiencies and prospects for the future. First, only the causal relationship between autoimmune diseases and ITP has been established. The specific mechanism and the causal relationship with disease severity and duration need further study. Second, the GWAS data used in this study is from the European population, which may limit the generalizability of this research results in other ethnic or geographical groups. With the continuous improvement of databases, it is expected that these findings can be confirmed in different populations in the future. Sensitivity analysis of a more extensive sample will also strengthen the results. Third, in this study, the MR-egger intercept analysis was utilized to examine horizontal pleiotropy. No significant impact of horizontal pleiotropy was observed. However, it is possible that the pleiotropic functions of certain genes have yet to be discovered. It is looked forward to that additional pleiotropy control methods

will be explored in future studies. Fourthly, due to the limitations of data sources, subgroup analysis and more comprehensive analysis of autoimmune diseases cannot be performed. This gap needs to be filled by the continuous improvement of future databases. The authors hope that researchers around the world consider these preliminary results and conduct multicenter clinical cohort studies to further understand the causal relationships between MS, CD, RA, SLE, AIH, PsO and ITP, as well as the mediating role of immune cells. Fifthly, sensitivity analyses of horizontal pleiotropy, heterogeneity, and the leave-one-out sensitivity analysis were performed in the study. Future research could be committed to employing more comprehensive sensitivity analysis methods and exploring and developing new methods for comprehensively evaluating and correcting various biases that might influence the research results. Finally, this study has revealed the mediating roles of certain immune cells. However, in the complex context of autoimmune diseases, there is a significant scarcity of research literature regarding the specific mechanisms by which these immune cells affect ITP. This situation suggests that in-depth exploration around this aspect can be carried out to fill the knowledge gap in this field.

Conclusion

In summary, through MR analysis, the authors have revealed the causal relationship between ten autoimmune diseases and ITP, and determined the causal relationship between eight autoimmune diseases and ITP. Therefore, it is of great significance to regularly monitor the blood routine of patients with MS, CD, RA, SLE, and AIH and take preventive measures. It also emphasizes the potential of a gluten-free diet for the treatment of ITP. At the same time, PsO, CD, and UC as protective factors for ITP, as well as the mediating role of immune cells, provide ideas and evidence for actively seeking new drug targets.

Eur J Rheumatol 2025;12:1-7

Yan et al. MR on AD, ITP and Immune Cells

References

1. Liu XG, Hou Y, Hou M. How we treat primary immune thrombocytopenia in adults. *J Hematol Oncol*. 2023;16(1):4. **[CrossRef]**
2. Cooper N, Ghanima W. Immune thrombocytopenia. *N Engl J Med*. 2019;381(10):945-955. **[CrossRef]**
3. Provan D, Semple JW. Recent advances in the mechanisms and treatment of immune thrombocytopenia. *EBiomedicine*. 2022;76:103820. **[CrossRef]**
4. Liu Z, Perry LA, Morgan V. The association between platelet indices and presence and severity of psoriasis: a systematic review and meta-analysis. *Clin Exp Med*. 2023;23(2):333-346. **[CrossRef]**
5. Yan SL, Russell J, Granger DN. Platelet activation and platelet-leukocyte aggregation elicited in experimental colitis are mediated by interleukin-6. *Inflamm Bowel Dis*. 2014;20(2):353-362. **[CrossRef]**
6. Hakim AJ, Machin SJ, Isenberg DA. Autoimmune thrombocytopenia in primary antiphospholipid syndrome and systemic lupus erythematosus: the response to splenectomy. *Semin Arthritis Rheum*. 1998;28(1):20-25. **[CrossRef]**
7. Tamaki K, Morishima S, Nakachi S, et al. An atypical case of late-onset systemic lupus erythematosus with systemic lymphadenopathy and severe autoimmune thrombocytopenia/neutropenia mimicking malignant lymphoma. *Int J Hematol*. 2017;105(4):526-531. **[CrossRef]**
8. Granier H, Bellard S, Nicolas X, Laborde JP, Talarmin F. Association sclérose en plaques et thrombopénie auto-immune [Association of multiple sclerosis and autoimmune thrombopenia]. *Rev Med Interne*. 2001;22(12):1271-1272. **[CrossRef]**
9. Segal JB, Powe NR. Prevalence of immune thrombocytopenia: analyses of administrative data. *J Thromb Haemost*. 2006;4(11):2377-2383. **[CrossRef]**
10. Ioachimescu AG, Makdissi A, Lichtin A, Zimmerman RS. Thyroid disease in patients with idiopathic thrombocytopenia: a cohort study. *Thyroid*. 2007;17(11):1137-1142. **[CrossRef]**
11. Wang L, Li L, Li C, et al. Significance of anti-HBc serological status in primary immune thrombocytopenia. *Br J Haematol*. 2022;196(4):1086-1095. **[CrossRef]**
12. Smith GD, Ebrahim S. 'Mendelian randomization': can genetic epidemiology contribute to understanding environmental determinants of disease? *Int J Epidemiol*. 2003;32(1):1-22. **[CrossRef]**
13. Carter AR, Sanderson E, Hammerton G, et al. Mendelian randomization for mediation analysis: current methods and challenges for implementation. *Eur J Epidemiol*. 2021;36(5):465-478. **[CrossRef]**
14. Guo YG, Zhang Y, Liu WL. The causal relationship between allergic diseases and heart failure: evidence from Mendelian randomization study. *PLoS One*. 2022;17(7):e0271985. **[CrossRef]**
15. Bowden J, Davey Smith G, Burgess S. Mendelian randomization with invalid instruments: effect estimation and bias detection through Egger regression. *Int J Epidemiol*. 2015;44(2):512-525. **[CrossRef]**
16. Bowden J, Davey Smith G, Haycock PC, Burgess S. Consistent estimation in Mendelian randomization with some invalid instruments using a weighted median estimator. *Genet Epidemiol*. 2016;40(4):304-314.
17. Burgess S, Scott RA, Timpson NJ, Davey Smith G, Thompson SG, EPIC- InterAct Consortium. Using published data in Mendelian randomization: a blueprint for efficient identification of causal risk factors. *Eur J Epidemiol*. 2015;30(7):543-552. **[CrossRef]**
18. Hartwig FP, Davey Smith G, Bowden J. Robust inference in summary data Mendelian randomization via the zero modal pleiotropy assumption. *Int J Epidemiol*. 2017;46(6):1985-1998.
19. Yao P, Iona A, Kartsonaki C, et al. China Kadoorie Biobank Collaborative Group. Conventional and genetic associations of adiposity with 1463 proteins in relatively lean Chinese adults. *Eur J Epidemiol*. 2023;38(10):1089-1103. **[CrossRef]**
20. MacKinnon DP, Lockwood CM, Hoffman JM, West SG, Sheets V. A comparison of methods to test mediation and other intervening variable effects. *Psychol Methods*. 2002;7(1):83-104. **[CrossRef]**
21. Saggini A, Chimenti S, Chiricozzi A. IL-6 as a druggable target in psoriasis: focus on pustular variants. *J Immunol Res*. 2014;2014:964069. **[CrossRef]**
22. Quintás-Cardama A, Kantarjian H, Cortes J, Verstovsek S. Janus kinase inhibitors for the treatment of myeloproliferative neoplasias and beyond. *Nat Rev Drug Discov*. 2011;10(2):127-140. **[CrossRef]**. Erratum in: *Nat Rev Drug Discov*. 2011;10(4):318. (https://doi.org/10.1038/nrd3264)
23. Magro F, Soares JB, Fernandes D. Venous thrombosis and prothrombotic factors in inflammatory bowel disease. *World J Gastroenterol*. 2014;20(17):4857-4872. **[CrossRef]**
24. Li H, Xin Q, Hong L, et al. Mendelian randomization analysis reveals causality of inflammatory bowel disease on risks of Henoch-Schönlein purpura and immune thrombocytopenia. *Dig Liver Dis*. 2024;56(1):92-97. **[CrossRef]**
25. Bibbò S, Fozza C, Pes GM, Rojas R, Manetti R, Dore MP. Increased frequency of immune thrombocytopenic purpura in coeliac disease and vice versa: a prospective observational study. *Gastroenterol Res Pract*. 2018;2018:4138434. **[CrossRef]**
26. Lejeune T, Meyer C, Abadie V. B lymphocytes contribute to celiac disease pathogenesis. *Gastroenterology*. 2021;160(7):2608-2610.e4. **[CrossRef]**
27. Pavlasova G, Mraz M. The regulation and function of CD20: an "enigma" of B-cell biology and targeted therapy. *Haematologica*. 2020;105(6):1494-1506. **[CrossRef]**
28. Arnold DM, Dentali F, Crowther MA, et al. Systematic review: efficacy and safety of rituximab for adults with idiopathic thrombocytopenic purpura. *Ann Intern Med*. 2007;146(1):25-33. **[CrossRef]**
29. Zheng NY, Wilson K, Wang X, et al. Human immunoglobulin selection associated with class switch and possible tolerogenic origins for C delta class-switched B cells. *J Clin Invest*. 2004;113(8):1188-1201. **[CrossRef]**
30. Koelsch K, Zheng NY, Zhang Q, et al. Mature B cells class switched to IgD are autoreactive in healthy individuals. *J Clin Invest*. 2007;117(6):1558-1565. **[CrossRef]**
31. Chen Y, Xu Y, Li H, et al. A novel anti-CD38 monoclonal antibody for treating immune thrombocytopenia. *N Engl J Med*. 2024;390(23):2178-2190. **[CrossRef]**

Supplementary Table 1. F statistics of SNPs screened by the three major assumptions in the forward two-sample MR analysis

Outcome	Exposure	SNP	FSTAT
ITP	PSO	rs11135059	85.36043001
ITP	PSO	rs11795343	32.55243687
ITP	PSO	rs12188300	123.8214213
ITP	PSO	rs12189871	2815.233983
ITP	PSO	rs12660617	41.87658387
ITP	PSO	rs2063111	30.81337019
ITP	PSO	rs2111485	30.49007842
ITP	PSO	rs3131627	84.89682172
ITP	PSO	rs34536443	48.27091061
ITP	PSO	rs4112787	29.9870581
ITP	PSO	rs55923651	37.73438044
ITP	PSO	rs6925732	192.6996645
ITP	PSO	rs72956432	30.30037576
ITP	PSO	rs7310615	30.27396575
ITP	PSO	rs8016947	48.65101542
ITP	PSO	rs8181551	30.23829116
ITP	PSO	rs9273151	104.8070446
ITP	PSO	rs9481169	45.59617349
ITP	MS	rs28746956	85.44825003
ITP	MS	rs4899257	29.87706063
ITP	MS	rs67382147	514.636834
ITP	MS	rs7759971	30.34318703
ITP	MS	rs9378141	90.78705762
ITP	CeD	rs10752747	34.17298747
ITP	CeD	rs10892258	45.24905693
ITP	CeD	rs11979905	31.06702607
ITP	CeD	rs12527282	54.34188339
ITP	CeD	rs12663317	208.2076571
ITP	CeD	rs130078	566.3945737
ITP	CeD	rs13030124	31.13362085
ITP	CeD	rs13119723	124.0897199
ITP	CeD	rs13198474	920.4400067
ITP	CeD	rs2441467	31.80731218
ITP	CeD	rs6498114	38.37488161
ITP	CeD	rs7162232	33.27874037
ITP	CeD	rs9296009	1086.930072
ITP	CeD	rs931	979.6147449
ITP	RA	rs1004095	1457.665613
ITP	RA	rs10790268	62.05340592
ITP	RA	rs10985070	31.79172627
ITP	RA	rs11085727	42.64291803

(Continued)

Outcome	Exposure	SNP	FSTAT
ITP	RA	rs11102694	295.8601695
ITP	RA	rs11574914	54.60672197
ITP	RA	rs11751696	108.4073148
ITP	RA	rs12764378	54.03428363
ITP	RA	rs13330176	33.03065199
ITP	RA	rs13426947	49.10624718
ITP	RA	rs1571878	61.27938238
ITP	RA	rs1858037	38.34522172
ITP	RA	rs187786174	40.26324817
ITP	RA	rs2069235	39.61354583
ITP	RA	rs2105325	32.79149815
ITP	RA	rs212389	37.18755467
ITP	RA	rs2233434	30.50131738
ITP	RA	rs2240336	36.59014565
ITP	RA	rs2523668	609.8837242
ITP	RA	rs2561477	38.56886246
ITP	RA	rs28411352	34.10950517
ITP	RA	rs28635831	42.37914515
ITP	RA	rs3087243	82.79731435
ITP	RA	rs34695944	56.91503609
ITP	RA	rs3778753	48.0596424
ITP	RA	rs4239702	57.06235681
ITP	RA	rs425482	71.2992075
ITP	RA	rs4452313	39.82818728
ITP	RA	rs4777188	54.6386311
ITP	RA	rs4936059	29.85036351
ITP	RA	rs537544	42.29276952
ITP	RA	rs58721818	76.29245736
ITP	RA	rs592390	34.73521003
ITP	RA	rs59716545	35.94474486
ITP	RA	rs624988	29.89356212
ITP	RA	rs706778	46.99027333
ITP	RA	rs7731626	96.65469068
ITP	RA	rs7770501	293.2003023
ITP	RA	rs8026898	71.80873804
ITP	RA	rs8032939	49.1015774
ITP	RA	rs8133843	33.82696448
ITP	RA	rs9268645	1281.570427
ITP	RA	rs9275512	2355.358861
ITP	RA	rs9310852	30.57042472
ITP	RA	rs9653442	48.36821074

(Continued)

Outcome	Exposure	SNP	FSTAT
ITP	SLE	rs10048743	31.45369142
ITP	SLE	rs10200680	34.19912501
ITP	SLE	rs1078324	83.27278954
ITP	SLE	rs10912578	63.4376319
ITP	SLE	rs1143679	211.9719673
ITP	SLE	rs12094036	32.23080007
ITP	SLE	rs12524498	31.06925638
ITP	SLE	rs13019891	374.7950672
ITP	SLE	rs13136219	39.36539753
ITP	SLE	rs13332649	70.1648941
ITP	SLE	rs143123127	31.27735957
ITP	SLE	rs1464446	66.93539487
ITP	SLE	rs150180633	181.1671805
ITP	SLE	rs17849501	264.4406023
ITP	SLE	rs2431697	58.00708332
ITP	SLE	rs2459611	33.36512753
ITP	SLE	rs2573219	187.4448347
ITP	SLE	rs268124	33.12922176
ITP	SLE	rs2736332	74.93703212
ITP	SLE	rs28361029	39.49812218
ITP	SLE	rs28361029	39.49812218
ITP	SLE	rs28834423	156.7802861
ITP	SLE	rs34703115	34.57980656
ITP	SLE	rs35000415	200.2013462
ITP	SLE	rs35251378	52.83680163
ITP	SLE	rs353608	44.21550815
ITP	SLE	rs3747093	57.80573825
ITP	SLE	rs389884	460.9261808
ITP	SLE	rs4274624	293.2102755
ITP	SLE	rs4388254	39.25393513
ITP	SLE	rs4661543	41.93674994
ITP	SLE	rs4916215	43.14558356
ITP	SLE	rs58688157	44.19203519
ITP	SLE	rs58721818	75.6451778
ITP	SLE	rs597808	30.40052104
ITP	SLE	rs6671847	47.12426711
ITP	SLE	rs6679677	52.38462379
ITP	SLE	rs6889239	76.50050697
ITP	SLE	rs7097397	42.10986435
ITP	SLE	rs73050535	33.01892623
ITP	SLE	rs73068668	29.96220774

(Continued)

Outcome	Exposure	SNP	FSTAT
ITP	SLE	rs7768653	48.61211132
ITP	SLE	rs7823055	150.086145
ITP	SLE	rs7899626	30.05732854
ITP	SLE	rs9274357	168.8845116
ITP	SLE	rs9852014	158.6053176
ITP	AIH	rs179247	62.54995317
ITP	AIH	rs6679677	45.91380473
ITP	AIH	rs72891915	32.32130872
ITP	AIH	rs9265890	69.3398438
ITP	AIH	rs9265890	69.3398438
ITP	AIH	rs9271671	37.66877457
ITP	AIH	rs9271671	37.66877457
ITP	AIH	rs9275576	122.6137002
ITP	AIH	rs942495	30.90487134
ITP	UC	rs10737481	32.56328354
ITP	UC	rs10807943	32.72913604
ITP	UC	rs181316459	80.13702061
ITP	UC	rs4676410	33.08676582
ITP	CD	rs13194642	30.58971146
ITP	CD	rs34022406	42.6516697
ITP	CD	rs62443225	46.41701054
ITP	CD	rs76176364	42.90970029

Supplementary Table 2. Results of Five Methods in the Forward Two-Sample MR Analysis

outcome	exposure	method	b	se	pval	or	or_lci95	or_uci95
ITP	PSO	MR Egger	-8.348E+00	4.501E+00	9.061E-02	2.368E-04	3.492E-08	1.606E+00
ITP	PSO	Weighted median	-7.830E+00	4.138E+00	5.843E-02	3.975E-04	1.195E-07	1.323E+00
ITP	PSO	IVW	-8.686E+00	3.639E+00	1.699E-02	1.690E-04	1.351E-07	2.115E-01
ITP	PSO	Simple mode	-6.385E+00	1.114E+01	5.772E-01	1.686E-03	5.513E-13	5.155E+06
ITP	PSO	Weighted mode	-7.398E+00	3.917E+00	8.331E-02	6.124E-04	2.838E-07	1.321E+00
ITP	CD	MR Egger	1.934E-01	2.575E-01	5.309E-01	1.213E+00	7.325E-01	2.010E+00
ITP	CD	Weighted median	-1.432E-01	9.862E-02	1.465E-01	8.666E-01	7.143E-01	1.051E+00
ITP	CD	IVW	-2.031E-01	9.861E-02	3.944E-02	8.162E-01	6.728E-01	9.902E-01
ITP	CD	Simple mode	-1.257E-01	1.244E-01	3.868E-01	8.819E-01	6.910E-01	1.125E+00
ITP	CD	Weighted mode	-1.348E-01	1.197E-01	3.422E-01	8.739E-01	6.911E-01	1.105E+00
ITP	UC	MR Egger	-4.163E-01	6.566E-01	6.403E-01	6.595E-01	1.821E-01	2.388E+00
ITP	UC	Weighted median	-3.898E-01	1.844E-01	3.458E-02	6.772E-01	4.717E-01	9.721E-01
ITP	UC	IVW	-3.435E-01	1.488E-01	2.095E-02	7.093E-01	5.299E-01	9.494E-01
ITP	UC	Simple mode	-4.801E-01	2.335E-01	1.761E-01	6.187E-01	3.915E-01	9.778E-01
ITP	UC	Weighted mode	-4.527E-01	2.127E-01	1.671E-01	6.359E-01	4.191E-01	9.648E-01
ITP	MS	MR Egger	4.450E+01	3.187E+01	2.570E-01	2.109E+19	1.574E-08	2.826E+46
ITP	MS	Weighted median	3.446E+01	1.956E+01	7.813E-02	9.254E+14	2.065E-02	4.147E+31
ITP	MS	IVW	3.861E+01	1.771E+01	2.923E-02	5.842E+16	4.951E+01	6.893E+31
ITP	MS	Simple mode	2.132E+01	2.963E+01	5.115E-01	1.824E+09	1.097E-16	3.033E+34
ITP	MS	Weighted mode	3.350E+01	2.249E+01	2.106E-01	3.542E+14	2.539E-05	4.940E+33
ITP	CeD	MR Egger	1.540E-01	8.250E-02	9.143E-02	1.167E+00	9.924E-01	1.371E+00
ITP	CeD	Weighted median	1.450E-01	7.141E-02	4.236E-02	1.156E+00	1.005E+00	1.330E+00
ITP	CeD	IVW	1.594E-01	5.636E-02	4.673E-03	1.173E+00	1.050E+00	1.310E+00
ITP	CeD	Simple mode	2.015E-01	1.119E-01	9.926E-02	1.223E+00	9.823E-01	1.523E+00
ITP	CeD	Weighted mode	1.501E-01	6.894E-02	5.210E-02	1.162E+00	1.015E+00	1.330E+00
ITP	RA	MR Egger	3.986E-02	6.690E-02	5.549E-01	1.041E+00	9.128E-01	1.186E+00
ITP	RA	Weighted median	7.330E-02	6.346E-02	2.481E-01	1.076E+00	9.502E-01	1.219E+00
ITP	RA	IVW	1.065E-01	4.446E-02	1.663E-02	1.112E+00	1.020E+00	1.214E+00
ITP	RA	Simple mode	2.093E-01	1.333E-01	1.246E-01	1.233E+00	9.494E-01	1.601E+00
ITP	RA	Weighted mode	8.093E-02	6.093E-02	1.920E-01	1.084E+00	9.622E-01	1.222E+00
ITP	SLE	MR Egger	6.880E-02	6.660E-02	3.078E-01	1.071E+00	9.401E-01	1.221E+00
ITP	SLE	Weighted median	3.073E-02	4.450E-02	4.897E-01	1.031E+00	9.451E-01	1.125E+00
ITP	SLE	IVW	6.608E-02	3.125E-02	3.446E-02	1.068E+00	1.005E+00	1.136E+00
ITP	SLE	Simple mode	2.426E-02	9.008E-02	7.890E-01	1.025E+00	8.587E-01	1.222E+00
ITP	SLE	Weighted mode	1.670E-02	6.542E-02	7.998E-01	1.017E+00	8.945E-01	1.156E+00
ITP	AIH	MR Egger	6.057E-01	1.582E-01	1.863E-02	1.833E+00	1.344E+00	2.499E+00
ITP	AIH	Weighted median	3.169E-01	8.601E-02	2.295E-04	1.373E+00	1.160E+00	1.625E+00
ITP	AIH	IVW	2.354E-01	8.109E-02	3.692E-03	1.265E+00	1.080E+00	1.483E+00
ITP	AIH	Simple mode	2.951E-01	1.753E-01	1.532E-01	1.343E+00	9.526E-01	1.894E+00
ITP	AIH	Weighted mode	3.471E-01	9.687E-02	1.582E-02	1.415E+00	1.170E+00	1.711E+00

Supplementary Table 3. Results of Five Methods in the Reverse Two-Sample Mendelian Randomization (MR) Analysis

outcome	exposure	method	b	se	pval
PSO	ITP	MR Egger	3.379E-04	1.071E-03	7.568E-01
PSO	ITP	Weighted median	-3.714E-05	3.442E-04	9.141E-01
PSO	ITP	Inverse variance weighted	-3.360E-04	6.212E-04	5.886E-01
PSO	ITP	Simple mode	1.196E-04	5.365E-04	8.265E-01
PSO	ITP	Weighted mode	-4.152E-05	5.235E-04	9.378E-01
CD	ITP	MR Egger	-7.001E-02	1.215E-01	5.737E-01
CD	ITP	Weighted median	-1.365E-01	7.530E-02	6.989E-02
CD	ITP	Inverse variance weighted	-1.038E-01	6.434E-02	1.067E-01
CD	ITP	Simple mode	-2.016E-01	1.350E-01	1.561E-01
CD	ITP	Weighted mode	-1.853E-01	1.249E-01	1.585E-01
UC	ITP	MR Egger	2.133E-02	5.986E-02	7.270E-01
UC	ITP	Weighted median	1.121E-02	4.433E-02	8.003E-01
UC	ITP	Inverse variance weighted	5.366E-03	3.270E-02	8.696E-01
UC	ITP	Simple mode	8.183E-03	7.223E-02	9.113E-01
UC	ITP	Weighted mode	1.390E-02	6.084E-02	8.224E-01
MS	ITP	MR Egger	1.091E-02	1.556E-02	5.219E-01
MS	ITP	Weighted median	2.928E-06	3.023E-04	9.923E-01
MS	ITP	Inverse variance weighted	1.097E-03	1.027E-03	2.857E-01
MS	ITP	Simple mode	9.732E-06	3.175E-04	9.767E-01
MS	ITP	Weighted mode	3.710E-05	3.391E-04	9.171E-01
RA	ITP	MR Egger	1.425E-02	7.038E-02	8.436E-01
RA	ITP	Weighted median	-2.705E-02	3.297E-02	4.119E-01
RA	ITP	Inverse variance weighted	-1.408E-02	2.716E-02	6.041E-01
RA	ITP	Simple mode	3.916E-03	5.791E-02	9.473E-01
RA	ITP	Weighted mode	-2.401E-02	4.261E-02	5.843E-01
SLE	ITP	MR Egger	-4.886E-02	2.073E-01	8.189E-01
SLE	ITP	Weighted median	3.606E-02	4.991E-02	4.700E-01
SLE	ITP	Inverse variance weighted	1.628E-01	1.220E-01	1.820E-01
SLE	ITP	Simple mode	8.921E-02	6.550E-02	2.031E-01
SLE	ITP	Weighted mode	5.395E-02	6.094E-02	3.967E-01
AIH	ITP	MR Egger	3.737E-02	8.872E-02	6.800E-01
AIH	ITP	Weighted median	1.277E-02	6.893E-02	8.530E-01
AIH	ITP	Inverse variance weighted	-5.926E-03	4.853E-02	9.028E-01
AIH	ITP	Simple mode	-8.453E-02	1.225E-01	5.005E-01
AIH	ITP	Weighted mode	-2.192E-02	1.090E-01	8.434E-01
AS	ITP	MR Egger	5.082E-02	2.740E-01	8.555E-01
AS	ITP	Weighted median	-1.483E-02	8.386E-02	8.596E-01
AS	ITP	Inverse variance weighted	-1.415E-01	1.480E-01	3.393E-01
AS	ITP	Simple mode	-2.217E-02	1.147E-01	8.493E-01
AS	ITP	Weighted mode	-9.995E-03	1.081E-01	9.276E-01
T1DM	ITP	MR Egger	-1.194E-01	2.113E-01	5.808E-01
T1DM	ITP	Weighted median	-4.374E-03	3.149E-02	8.895E-01
T1DM	ITP	Inverse variance weighted	1.175E-01	1.179E-01	3.187E-01
T1DM	ITP	Simple mode	-5.773E-03	5.045E-02	9.104E-01
T1DM	ITP	Weighted mode	-1.068E-02	4.631E-02	8.207E-01

Supplementary Table 4. Results of MR-egger Intercept Analysis in the Forward Two-Sample MR Analysis

outcome	exposure	egger_intercept	se	pval
ITP	PSO	-2.699E-03	2.120E-02	9.010E-01
ITP	MS	-1.067E-02	4.801E-02	8.384E-01
ITP	CeD	2.277E-03	2.552E-02	9.307E-01
ITP	RA	1.822E-02	1.368E-02	1.909E-01
ITP	SLE	-1.109E-03	2.390E-02	9.632E-01
ITP	AIH	-2.170E-01	8.566E-02	6.441E-02
ITP	UC	1.806E-02	1.544E-01	9.259E-01
ITP	CD	-2.825E-01	1.743E-01	2.466E-01

Supplementary Table 5. Results of Cochran's Q Test in the Forward Two-Sample MR Analysis

outcome	exposure	method	Q_pval
ITP	PSO	MR Egger	5.667E-01
ITP	PSO	Inverse variance weighted	6.496E-01
ITP	CD	MR Egger	3.815E-01
ITP	CD	Inverse variance weighted	2.077E-01
ITP	UC	MR Egger	1.552E-01
ITP	UC	Inverse variance weighted	3.591E-01
ITP	MS	MR Egger	6.750E-01
ITP	MS	Inverse variance weighted	8.122E-01
ITP	CeD	MR Egger	7.427E-01
ITP	CeD	Inverse variance weighted	8.132E-01
ITP	SLE	MR Egger	1.994E-01
ITP	SLE	Inverse variance weighted	2.312E-01
ITP	RA	MR Egger	9.232E-01
ITP	RA	Inverse variance weighted	9.015E-01
ITP	AIH	MR Egger	6.353E-01
ITP	AIH	Inverse variance weighted	1.102E-01

Supplementary Table 6. Results of Five Methods in the Mediated-to-Outcome Two-Sample Mendelian Randomization (MR) Analysis

outcome	exposure	method	b	se	pval	or	or_lci95	or_uci95
ITP	Switched memory B cell %lymphocyte	MR Egger	-9.390E+00	5.876E+00	3.560E-01	8.352E-05	8.319E-10	8.385E+00
ITP	Switched memory B cell %lymphocyte	Weighted median	5.321E-01	2.700E-01	4.871E-02	1.703E+00	1.003E+00	2.890E+00
ITP	Switched memory B cell %lymphocyte	IVW	5.028E-01	2.419E-01	3.768E-02	1.653E+00	1.029E+00	2.656E+00
ITP	Switched memory B cell %lymphocyte	Simple mode	6.568E-01	3.407E-01	1.937E-01	1.929E+00	9.892E-01	3.760E+00
ITP	Switched memory B cell %lymphocyte	Weighted mode	6.250E-01	3.428E-01	2.099E-01	1.868E+00	9.542E-01	3.658E+00
ITP	B cell %CD3- lymphocyte	MR Egger	-1.946E-01	8.518E-02	2.627E-01	8.232E-01	6.966E-01	9.727E-01
ITP	B cell %CD3- lymphocyte	Weighted median	-1.724E-01	8.264E-02	3.693E-02	8.416E-01	7.158E-01	9.896E-01
ITP	B cell %CD3- lymphocyte	IVW	-1.702E-01	7.343E-02	2.044E-02	8.435E-01	7.304E-01	9.740E-01
ITP	B cell %CD3- lymphocyte	Simple mode	-1.089E-01	1.378E-01	5.120E-01	8.968E-01	6.845E-01	1.175E+00
ITP	B cell %CD3- lymphocyte	Weighted mode	-1.787E-01	8.337E-02	1.653E-01	8.364E-01	7.103E-01	9.848E-01
ITP	CD20 on IgD+ CD38+ B cell	MR Egger	-2.931E-01	3.995E-01	5.163E-01	7.459E-01	3.409E-01	1.632E+00
ITP	CD20 on IgD+ CD38+ B cell	Weighted median	-3.818E-01	1.506E-01	1.124E-02	6.826E-01	5.081E-01	9.170E-01
ITP	CD20 on IgD+ CD38+ B cell	IVW	-4.205E-01	1.235E-01	6.618E-04	6.567E-01	5.155E-01	8.366E-01
ITP	CD20 on IgD+ CD38+ B cell	Simple mode	-4.638E-01	2.042E-01	8.564E-02	6.289E-01	4.214E-01	9.385E-01
ITP	CD20 on IgD+ CD38+ B cell	Weighted mode	-3.940E-01	1.702E-01	8.160E-02	6.743E-01	4.831E-01	9.414E-01
ITP	CD20 on IgD+ CD24- B cell	MR Egger	-4.965E-01	8.419E-01	5.810E-01	6.086E-01	1.169E-01	3.170E+00
ITP	CD20 on IgD+ CD24- B cell	Weighted median	-5.752E-01	1.577E-01	2.654E-04	5.626E-01	4.130E-01	7.664E-01
ITP	CD20 on IgD+ CD24- B cell	IVW	-5.589E-01	1.195E-01	2.885E-06	5.718E-01	4.524E-01	7.227E-01
ITP	CD20 on IgD+ CD24- B cell	Simple mode	-5.710E-01	2.303E-01	4.787E-02	5.649E-01	3.597E-01	8.873E-01
ITP	CD20 on IgD+ CD24- B cell	Weighted mode	-4.283E-01	2.039E-01	8.045E-02	6.516E-01	4.369E-01	9.718E-01
ITP	CD20 on naive-mature B cell	MR Egger	-9.023E-01	9.519E-01	3.798E-01	4.056E-01	6.279E-02	2.620E+00
ITP	CD20 on naive-mature B cell	Weighted median	-3.440E-01	1.678E-01	4.036E-02	7.089E-01	5.103E-01	9.850E-01
ITP	CD20 on naive-mature B cell	IVW	-4.269E-01	1.357E-01	1.652E-03	6.526E-01	5.002E-01	8.513E-01
ITP	CD20 on naive-mature B cell	Simple mode	-3.735E-01	2.589E-01	1.924E-01	6.883E-01	4.143E-01	1.143E+00
ITP	CD20 on naive-mature B cell	Weighted mode	-3.433E-01	2.233E-01	1.681E-01	7.094E-01	4.579E-01	1.099E+00
ITP	CD20 on IgD+ B cell	MR Egger	-2.708E-01	1.083E+00	8.109E-01	7.627E-01	9.129E-02	6.373E+00
ITP	CD20 on IgD+ B cell	Weighted median	-3.313E-01	1.533E-01	3.075E-02	7.180E-01	5.316E-01	9.698E-01
ITP	CD20 on IgD+ B cell	IVW	-4.044E-01	1.292E-01	1.746E-03	6.674E-01	5.181E-01	8.597E-01
ITP	CD20 on IgD+ B cell	Simple mode	-3.873E-01	2.516E-01	1.677E-01	6.789E-01	4.146E-01	1.112E+00
ITP	CD20 on IgD+ B cell	Weighted mode	-3.305E-01	2.060E-01	1.526E-01	7.186E-01	4.799E-01	1.076E+00
ITP	CD25 on IgD+ CD38+ B cell	MR Egger	-6.980E-01	8.518E-01	5.630E-01	4.976E-01	9.371E-02	2.642E+00
ITP	CD25 on IgD+ CD38+ B cell	Weighted median	7.497E-01	2.717E-01	5.795E-03	2.116E+00	1.243E+00	3.605E+00
ITP	CD25 on IgD+ CD38+ B cell	IVW	5.717E-01	2.877E-01	4.692E-02	1.771E+00	1.008E+00	3.113E+00
ITP	CD25 on IgD+ CD38+ B cell	Simple mode	8.641E-01	3.801E-01	1.509E-01	2.373E+00	1.126E+00	4.998E+00
ITP	CD25 on IgD+ CD38+ B cell	Weighted mode	8.622E-01	4.140E-01	1.727E-01	2.368E+00	1.052E+00	5.331E+00

Supplementary Table 7. Results of MR-egger Intercept Analysis in the Mediated-to-Outcome Two-Sample MR Analysis

outcome	mediator	egger_intercept	se	pval
ITP	CD25 on IgD+ CD38+ B cell	3.014E-01	1.953E-01	3.660E-01
ITP	B cell %CD3- lymphocyte	2.409E-02	4.267E-02	6.729E-01
ITP	Switched memory B cell %lymphocyte	1.479E+00	8.779E-01	3.410E-01
ITP	CD20 on IgD+ CD38+ B cell	-2.757E-02	8.227E-02	7.596E-01
ITP	CD20 on IgD+ CD24- B cell	1.073E-01	2.141E-01	6.507E-01
ITP	CD20 on naive-mature B cell	7.804E-02	2.259E-01	7.471E-01
ITP	CD20 on IgD+ B cell	-1.817E-02	2.628E-01	9.482E-01

Supplementary Table 8. Results of Cochran's Q Test in the Mediated-to-Outcome Two-Sample MR Analysis

mediator	outcome	method	Q_pval
B cell %CD3- lymphocyte	ITP	MR Egger	8.593E-01
B cell %CD3- lymphocyte	ITP	Inverse variance weighted	8.394E-01
Switched memory B cell %lymphocyte	ITP	MR Egger	9.103E-01
Switched memory B cell %lymphocyte	ITP	Inverse variance weighted	2.404E-01
CD20 on IgD+ CD38+ B cell	ITP	MR Egger	4.244E-01
CD20 on IgD+ CD38+ B cell	ITP	Inverse variance weighted	5.735E-01
CD20 on IgD+ CD24- B cell	ITP	MR Egger	4.483E-01
CD20 on IgD+ CD24- B cell	ITP	Inverse variance weighted	5.740E-01
CD20 on naive-mature B cell	ITP	MR Egger	1.740E-01
CD20 on naive-mature B cell	ITP	Inverse variance weighted	2.565E-01
CD20 on IgD+ B cell	ITP	MR Egger	1.488E-01
CD20 on IgD+ B cell	ITP	Inverse variance weighted	2.380E-01
CD25 on IgD+ CD38+ B cell	ITP	MR Egger	2.989E-01
CD25 on IgD+ CD38+ B cell	ITP	Inverse variance weighted	1.612E-01

Supplementary Table 9. F statistics of SNPs screened by the three major assumptions in the Mediated-to-Outcome Two-Sample MR Analysis

mediator	outcome	SNP	F
CD20 on IgD+ CD24- B cel	ITP	rs2066399	49.04712552
CD20 on IgD+ CD24- B cell	ITP	rs4939384	67.91569126
CD20 on IgD+ CD24- B cell	ITP	rs62405562	46.30813906
CD20 on IgD+ CD24- B cell	ITP	rs72836542	37.51506001
CD20 on IgD+ CD24- B cell	ITP	rs9270560	32.4475341
B cell %CD3- lymphocyte	ITP	rs11954223	34.59274461
B cell %CD3- lymphocyte	ITP	rs9520836	33.30910286
B cell %CD3- lymphocyte	ITP	rs9916257	51.00120326
Switched memory B cell %lymphocyte	ITP	rs11653761	35.86475345
Switched memory B cell %lymphocyte	ITP	rs7840395	32.60277889
Switched memory B cell %lymphocyte	ITP	rs9520836	39.93441211
CD20 on IgD+ CD38+ B cell	ITP	rs2066399	111.3256138
CD20 on IgD+ CD38+ B cell	ITP	rs34486765	40.94537935
CD20 on IgD+ CD38+ B cell	ITP	rs72836542	31.19900977
CD20 on IgD+ CD38+ B cell	ITP	rs7768875	30.80316584
CD20 on IgD+ CD38+ B cell	ITP	rs7939177	51.98624573
CD20 on naive-mature B cell	ITP	rs1941018	62.69515809
CD20 on naive-mature B cell	ITP	rs30003	31.95793155
CD20 on naive-mature B cell	ITP	rs388354	30.27853048
CD20 on naive-mature B cell	ITP	rs62405562	42.19948692
CD20 on naive-mature B cell	ITP	rs6910382	49.32584326
CD20 on naive-mature B cell	ITP	rs72836542	34.1829056
CD20 on naive-mature B cell	ITP	rs9270560	33.82123153
CD20 on IgD+ B cell	ITP	rs12212931	49.49938326
CD20 on IgD+ B cell	ITP	rs30003	36.80822465
CD20 on IgD+ B cell	ITP	rs4939384	65.45364565
CD20 on IgD+ B cell	ITP	rs62405562	44.83931007
CD20 on IgD+ B cell	ITP	rs72836542	32.00091419
CD20 on IgD+ B cell	ITP	rs9270560	36.62291902
CD25 on IgD+ CD38+ B cell	ITP	rs3793662	39.11660926
CD25 on IgD+ CD38+ B cell	ITP	rs62626323	76.31274732
CD25 on IgD+ CD38+ B cell	ITP	rs709589	64.64971199

**Supplementary Table 10.** F statistics of SNPs screened by the three major assumptions in the Exposure-to-Mediator Two-Sample MR Analysis

| mediator	exposure	SNP	F
CD20 on IgD+ CD24- B cell	CD	rs13194642	30.58971146
CD20 on IgD+ CD24- B cell	CD	rs34022406	42.6516697
CD20 on IgD+ CD24- B cell	CD	rs62443225	46.41701054
CD20 on IgD+ CD24- B cell	CD	rs76176364	42.90970029
CD20 on IgD+ B cell	CD	rs13194642	30.58971146
CD21 on IgD+ B cell	CD	rs34022406	42.6516697
CD22 on IgD+ B cell	CD	rs62443225	46.41701054
CD23 on IgD+ B cell	CD	rs76176364	42.90970029
CD20 on IgD+ CD24- B cell	CeD	rs10752747	34.17298747
CD20 on IgD+ CD24- B cell	CeD	rs10892258	45.24905693
CD20 on IgD+ CD24- B cell	CeD	rs11979905	31.06702607
CD20 on IgD+ CD24- B cell	CeD	rs12527282	54.34188339
CD20 on IgD+ CD24- B cell	CeD	rs12663317	208.2076571
CD20 on IgD+ CD24- B cell	CeD	rs130078	566.3945737
CD20 on IgD+ CD24- B cell	CeD	rs13030124	31.13362085
CD20 on IgD+ CD24- B cell	CeD	rs13119723	124.0897199
CD20 on IgD+ CD24- B cell	CeD	rs13198474	920.4400067
CD20 on IgD+ CD24- B cell	CeD	rs2441467	31.80731218
CD20 on IgD+ CD24- B cell	CeD	rs6498114	38.37488161
CD20 on IgD+ CD24- B cell	CeD	rs7162232	33.27874037
CD20 on IgD+ CD24- B cell	CeD	rs9296009	1086.930072
CD20 on IgD+ CD24- B cell	CeD	rs931	979.6147449
CD20 on IgD+ CD38+ B cell	CeD	rs10752747	34.17298747
CD20 on IgD+ CD38+ B cell	CeD	rs10892258	45.24905693
CD20 on IgD+ CD38+ B cell	CeD	rs11979905	31.06702607
CD20 on IgD+ CD38+ B cell	CeD	rs12527282	54.34188339
CD20 on IgD+ CD38+ B cell	CeD	rs12663317	208.2076571
CD20 on IgD+ CD38+ B cell	CeD	rs130078	566.3945737
CD20 on IgD+ CD38+ B cell	CeD	rs13030124	31.13362085
CD20 on IgD+ CD38+ B cell	CeD	rs13119723	124.0897199
CD20 on IgD+ CD38+ B cell	CeD	rs13198474	920.4400067
CD20 on IgD+ CD38+ B cell	CeD	rs2441467	31.80731218
CD20 on IgD+ CD38+ B cell	CeD	rs6498114	38.37488161
CD20 on IgD+ CD38+ B cell	CeD	rs7162232	33.27874037
CD20 on IgD+ CD38+ B cell	CeD	rs9296009	1086.930072
CD20 on IgD+ CD38+ B cell	CeD	rs931	979.6147449
CD20 on naive-mature B cell	CeD	rs10752747	34.17298747
CD20 on naive-mature B cell	CeD	rs10892258	45.24905693
CD20 on naive-mature B cell	CeD	rs11979905	31.06702607
CD20 on naive-mature B cell	CeD	rs12527282	54.34188339
CD20 on naive-mature B cell	CeD	rs12663317	208.2076571

(Continued)

Supplementary Table 10. F statistics of SNPs screened by the three major assumptions in the Exposure-to-Mediator Two-Sample MR Analysis (*Continued*)

mediator	exposure	SNP	F
CD20 on naive-mature B cell	CeD	rs130078	566.3945737
CD20 on naive-mature B cell	CeD	rs13030124	31.13362085
CD20 on naive-mature B cell	CeD	rs13119723	124.0897199
CD20 on naive-mature B cell	CeD	rs13198474	920.4400067
CD20 on naive-mature B cell	CeD	rs2441467	31.80731218
CD20 on naive-mature B cell	CeD	rs6498114	38.37488161
CD20 on naive-mature B cell	CeD	rs7162232	33.27874037
CD20 on naive-mature B cell	CeD	rs9296009	1086.930072
CD20 on naive-mature B cell	CeD	rs931	979.6147449
CD20 on IgD+ B cell	CeD	rs10752747	34.17298747
CD20 on IgD+ B cell	CeD	rs10892258	45.24905693
CD20 on IgD+ B cell	CeD	rs11979905	31.06702607
CD20 on IgD+ B cell	CeD	rs12527282	54.34188339
CD20 on IgD+ B cell	CeD	rs12663317	208.2076571
CD20 on IgD+ B cell	CeD	rs130078	566.3945737
CD20 on IgD+ B cell	CeD	rs13030124	31.13362085
CD20 on IgD+ B cell	CeD	rs13119723	124.0897199
CD20 on IgD+ B cell	CeD	rs13198474	920.4400067
CD20 on IgD+ B cell	CeD	rs2441467	31.80731218
CD20 on IgD+ B cell	CeD	rs6498114	38.37488161
CD20 on IgD+ B cell	CeD	rs7162232	33.27874037
CD20 on IgD+ B cell	CeD	rs9296009	1086.93030072
CD20 on IgD+ B cell	CeD	rs931	979.6147 449

Supplementary Table 11. Results of Five Methods in the Exposure-to-Mediator Two-Sample Mendelian Randomization (MR) Analysis

mediator	exposure	method	b	se	pval	or	or_lci95	or_uci95
CD20 on IgD+ B cell	CD	MR Egger	4.071E-02	2.136E-01	8.664E-01	1.042E+00	6.853E-01	1.583E+00
CD20 on IgD+ B cell	CD	Weighted median	1.214E-01	4.951E-02	1.423E-02	1.129E+00	1.025E+00	1.244E+00
CD20 on IgD+ B cell	CD	IVW	1.012E-01	4.045E-02	1.238E-02	1.106E+00	1.022E+00	1.198E+00
CD20 on IgD+ B cell	CD	Simple mode	1.179E-01	7.188E-02	1.994E-01	1.125E+00	9.773E-01	1.295E+00
CD20 on IgD+ B cell	CD	Weighted mode	1.089E-01	5.571E-02	1.457E-01	1.115E+00	9.997E-01	1.244E+00
CD20 on IgD+ CD24- B cell	CD	MR Egger	2.152E-01	2.522E-01	4.835E-01	1.240E+00	7.564E-01	2.033E+00
CD20 on IgD+ CD24- B cell	CD	Weighted median	9.416E-02	5.272E-02	7.412E-02	1.099E+00	9.909E-01	1.218E+00
CD20 on IgD+ CD24- B cell	CD	IVW	1.063E-01	4.079E-02	9.172E-03	1.112E+00	1.027E+00	1.205E+00
CD20 on IgD+ CD24- B cell	CD	Simple mode	1.200E-01	6.705E-02	1.714E-01	1.128E+00	9.887E-01	1.286E+00
CD20 on IgD+ CD24- B cell	CD	Weighted mode	9.026E-02	4.924E-02	1.642E-01	1.094E+00	9.938E-01	1.205E+00
CD20 on IgD+ B cell	CeD	MR Egger	-1.821E-01	4.845E-02	3.728E-03	8.335E-01	7.580E-01	9.165E-01
CD20 on IgD+ B cell	CeD	Weighted median	-1.453E-01	3.806E-02	1.341E-04	8.647E-01	8.026E-01	9.317E-01
CD20 on IgD+ B cell	CeD	IVW	-1.207E-01	3.131E-02	1.152E-04	8.863E-01	8.335E-01	9.424E-01
CD20 on IgD+ B cell	CeD	Simple mode	-1.178E-01	6.805E-02	1.115E-01	8.889E-01	7.779E-01	1.016E+00
CD20 on IgD+ B cell	CeD	Weighted mode	-1.431E-01	3.765E-02	2.941E-03	8.667E-01	8.050E-01	9.330E-01
CD20 on IgD+ CD24- B cell	CeD	MR Egger	-1.603E-01	4.829E-02	7.753E-03	8.519E-01	7.749E-01	9.365E-01
CD20 on IgD+ CD24- B cell	CeD	Weighted median	-1.363E-01	3.688E-02	2.188E-04	8.726E-01	8.117E-01	9.380E-01
CD20 on IgD+ CD24- B cell	CeD	IVW	-1.213E-01	3.121E-02	1.018E-04	8.858E-01	8.332E-01	9.417E-01
CD20 on IgD+ CD24- B cell	CeD	Simple mode	-1.294E-01	6.329E-02	6.560E-02	8.786E-01	7.761E-01	9.947E-01
CD20 on IgD+ CD24- B cell	CeD	Weighted mode	-1.365E-01	3.682E-02	3.455E-03	8.724E-01	8.117E-01	9.377E-01
CD20 on IgD+ CD38+ B cell	CeD	MR Egger	-1.460E-01	4.833E-02	1.287E-02	8.641E-01	7.860E-01	9.500E-01
CD20 on IgD+ CD38+ B cell	CeD	Weighted median	-1.307E-01	3.697E-02	4.059E-04	8.774E-01	8.161E-01	9.434E-01
CD20 on IgD+ CD38+ B cell	CeD	IVW	-1.311E-01	3.108E-02	2.460E-05	8.771E-01	8.253E-01	9.322E-01
CD20 on IgD+ CD38+ B cell	CeD	Simple mode	-6.439E-02	7.719E-02	4.219E-01	9.376E-01	8.060E-01	1.091E+00
CD20 on IgD+ CD38+ B cell	CeD	Weighted mode	-1.277E-01	3.689E-02	5.309E-03	8.801E-01	8.187E-01	9.461E-01
CD20 on naive-mature B cell	CeD	MR Egger	-1.736E-01	4.819E-02	4.836E-03	8.407E-01	7.649E-01	9.239E-01
CD20 on naive-mature B cell	CeD	Weighted median	-1.434E-01	3.689E-02	1.012E-04	8.664E-01	8.060E-01	9.314E-01
CD20 on naive-mature B cell	CeD	IVW	-1.277E-01	3.115E-02	4.110E-05	8.801E-01	8.280E-01	9.355E-01
CD20 on naive-mature B cell	CeD	Simple mode	-1.563E-01	6.324E-02	3.100E-02	8.553E-01	7.556E-01	9.681E-01
CD20 on naive-mature B cell	CeD	Weighted mode	-1.440E-01	3.674E-02	2.392E-03	8.659E-01	8.057E-01	9.305E-01

Supplementary Figure 1. The forest plot shows the causal effects of each SNP of PSO on ITP.

Supplementary Figure 2. The forest plot shows the causal effects of each SNP of CD on ITP.

**Supplementary Figure 3.** The forest plot shows the causal effects of each SNP of UC on ITP.

**Supplementary Figure 4.** The forest plot shows the causal effects of each SNP of MS on ITP.

Supplementary Figure 5. The forest plot shows the causal effects of each SNP of CeD on ITP.

Supplementary Figure 6. The forest plot shows the causal effects of each SNP of RA on ITP.

Supplementary Figure 7. The forest plot shows the causal effects of each SNP of SLE on ITP.

Supplementary Figure 8. The forest plot shows the causal effects of each SNP of AIH on ITP.

Supplementary Figure 9. The scatter plot for causal estimate of PSO on ITP by MR analysis. abscissa: SNP effect on PSO. ordinate: SNP effect on ITP.

Supplementary Figure 10. The scatter plot for causal estimate of CD on ITP by MR analysis. abscissa: SNP effect on CD. ordinate: SNP effect on ITP.

Supplementary Figure 11. The scatter plot for causal estimate of UC on ITP by MR analysis. abscissa: SNP effect on UC. ordinate: SNP effect on ITP.

Supplementary Figure 12. The scatter plot for causal estimate of MS on ITP by MR analysis. abscissa: SNP effect on MS. ordinate: SNP effect on ITP.

Supplementary Figure 13. The scatter plot for causal estimate of CeD on ITP by MR analysis. abscissa: SNP effect on CeD. ordinate: SNP effect on ITP.

Supplementary Figure 14. The scatter plot for causal estimate of RA on ITP by MR analysis. abscissa: SNP effect on RA. ordinate: SNP effect on ITP.

Supplementary Figure 15. The scatter plot for causal estimate of SLE on ITP by MR analysis. abscissa: SNP effect on SLE. ordinate: SNP effect on ITP.

Supplementary Figure 16. The scatter plot for causal estimate of AIH on ITP by MR analysis. abscissa: SNP effect on AIH. ordinate: SNP effect on ITP.

Supplementary Figure 17. Leave-one-out analyse for the causal estimates of PSO on ITP.

Supplementary Figure 18. Leave-one-out analyse for the causal estimates of CD on ITP.

Supplementary Figure 19. Leave-one-out analyse for the causal estimates ofUC on ITP.

**Supplementary Figure 20.** Leave-one-out analyse for the causal estimates ofr MS on ITP.

Supplementary Figure 21. Leave-one-out analyse for the causal estimates of CeD on ITP.

Supplementary Figure 22. Leave-one-out analyse for the causal estimates of RA on ITP.

Supplementary Figure 23. Leave-one-out analyse for the causal estimates of SLE on ITP.

Supplementary Figure 24. Leave-one-out analyse for the causal estimates of AIH on ITP

Supplementary Figure 25. Funnel plots demonstrating the overall heterogeneity of MR estimates for the effects of PSO on ITP.

Supplementary Figure 26. Funnel plots demonstrating the overall heterogeneity of MR estimates for the effects of CD on ITP.

Supplementary Figure 27. Funnel plots demonstrating the overall heterogeneity of MR estimates for the effects of UC on ITP.


Supplementary Figure 28. Funnel plots demonstrating the overall heterogeneity of MR estimates for the effects of MS on ITP.

Supplementary Figure 29. Funnel plots demonstrating the overall heterogeneity of MR estimates for the effects of CeD on ITP.

Supplementary Figure 30. Funnel plots demonstrating the overall heterogeneity of MR estimates for the effects of RA on ITP.

Supplementary Figure 31. Funnel plots demonstrating the overall heterogeneity of MR estimates for the effects of SLE on ITP.

Supplementary Figure 32. Funnel plots demonstrating the overall heterogeneity of MR estimates for the effects of AIH on ITP.